New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 15, 2013
06:30 EDTMDCOThe Medicines Co. initiated with an Outperform at Credit Suisse
Target $38.
News For MDCO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 2, 2015
13:19 EDTMDCOCantor lowers sales assumptions for Eagle's Angiomax version
After an appeals court invalidated the Angiomax patents held by The Medicines Company (MDCO), Cantor Fitzgerald lowered its price target for Eagle Pharmaceuticals (EGRX) to $92 from $95 to reflect more modest sales assumptions for the company's version of Angiomax. Cantor had previously modeled a more favorable for Eagle whereby there were no generic entrants until 2019. The firm, however, still sees the stock as undervalued and keeps a Buy rating on the name.
12:40 EDTMDCOMedicines Co. says appeals court rules against company in Angiomax litigation
Subscribe for More Information
10:17 EDTMDCOAppeals court reverses lower court patent ruling in Medicines Co. case
The Medicines Company (MDCO) owns U.S. patent no. 7,582,727 and U.S. patent no. 7,598,343, which relate to the drug bivalirudin, a synthetic peptide used as an anti-coagulant that the company sells under the Angiomax brand. On August 19, 2010, The Medicines Company sued Hospira (HSP), alleging that two of Hospira’s ANDA filings infringe claims 1–3, 7–10, and 17 of the ’727 patent and claims 1–3 and 7–11 of the ’343 patent. A district court previously construed the asserted claims and, after a bench trial, found the patents not infringed and not invalid as obvious, indefinite, or under the on-sale bar. The Medicines Company appealed the U.S. District Court for the District of Delaware’s claim construction and non-infringement findings, while Hospira, crossappealed the district court’s determination that the asserted claims are not invalid under the on-sale bar, obviousness, or indefiniteness. The U.S. Court of Appeals for the Federal Circuit has now concluded that the district court "clearly erred" in finding that the bivalirudin batches prepared by Ben Venue Laboratories before the critical date were not sold to The Medicines Company and were prepared primarily for an experimental purpose. Accordingly, the federal appeals court reversed the district court’s validity determination and held the asserted claims invalid under the onsale bar. Shares of Medicines Co., which initially fell amid headlines regarding the ruling, are now up 4.5% to $29.61, while Hospira is flat at $88.90.
10:04 EDTMDCOHigh option volume stocks
Subscribe for More Information
09:57 EDTMDCOMedicines Co. loses appeal in Hospira suit over Angiomax patents, Bloomberg says
Subscribe for More Information
09:50 EDTMDCOThe Medicines Co. drops 3.2% to $27.43 in early trading
Subscribe for More Information
June 26, 2015
07:15 EDTMDCOMedicines Co. considering strategic options for European unit, Bloomberg reports
The Medicines Co. is working with advisers from Rothschild on a review of strategic options for its European business, according to Bloomberg, citing people familiar with the matter. The review, which is at an advanced stage, may lead to a sale, licensing agreement or partnership, the report added. Reference Link
June 25, 2015
14:38 EDTMDCOMedicines Co. considering strategic options for European unit, Bloomberg says
June 22, 2015
16:37 EDTMDCOThe Medicines Co. to hold a conference call
Subscribe for More Information
14:33 EDTMDCOThe Medicines Co. antiplatelet drug approved by FDA
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use